Biotech | March 29, 2022
Dupixent is a star in Sanofi’s immunology strategy
Dupixent peak sales ambition raised to more than €13 billion
Dupixent peak sales ambition raised to more than €13 billion
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
Novel tool bypasses plasmid-based expression to increase stability and significantly reduce development time for a variety of synthetic biotechnology products
John Shaw, who is a Glasgow University graduate, along with his wife Kiran Mazumdar-Shaw had gifted US $ 7.5 million to the university in July 2019
The funding will accelerate the AI-driven healthcare company's market expansion into the global market and support new product development
New collaboration will help customers reach sustainability goals for high-performance Udel PSU polymers in demanding applications.
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Launched in the year 2018, MedEngage Scholarship Program is aimed at nurturing and nourishing medical talent in India
The fund will take equity positions in India-focused healthcare and life sciences-related companies
Subscribe To Our Newsletter & Stay Updated
